Biogen, the manufacturer of the controversial drug for Alzheimer’s disease (AD) aducanumab (Aduhelm) needs to cut its $56,000 annual cost and speed the pace of research to determine whether the medication actually keeps the disease at bay.
These are among the key recommendations of a report released today by the Institute for Clinical and Economic Review (ICER). The institute also suggested that Medicare could limit initial coverage of aducanumab to patients enrolled in a randomized clinical trial
